Research study focused on the safety and efficacy of Lutetium-177-PSMA-I&T in Metastatic Castration-Resistant Prostate Cancer

Thank you for your interest in Curium's ECLIPSE research study! Participating in this study presents an investigational therapy option for patients that may help advance innovation in metastatic castration-resistant prostate cancer treatment.



The purpose of this research study is to compare the safety and efficacy of Lutetium Lu-177-PSMA-I&T versus standard-of-care hormone therapy in patients with metastatic castration-resistant prostate cancer.

Why Target PSMA?

Prostate-specific membrane antigen (PSMA) is found in large numbers at the surface of prostate tumor cells. The study drug, Lutetium Lu-177-PSMA-I&T, attaches to the PSMA and is taken inside the tumor cell. The radiation inside the tumor cell causes DNA damage which results in the tumor cell death.

All Patients Receive Treatment

Patients will be randomized using a 2:1 ratio of study medication to standard-of-care hormone therapy for metastatic castration-resistant prostate cancer. Participants receiving standard-of-care treatment may have the option to receive the study drug, Lutetium Lu-177-PSMA-I&T, if disease progression is detected.

Study Overview - What can you expect?

How do I know if I am eligible?